{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:24:08Z","timestamp":1787635448980,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>The global surge in myopia prevalence, particularly the rising incidence of high myopia and its associated blinding complications\u2014including myopic maculopathy, retinal detachment, and glaucoma\u2014has transformed this condition into a pressing public health priority. Atropine, the most extensively studied pharmacological intervention for myopia control, now stands at a critical crossroads. The shift from high-concentration to low-concentration formulations has markedly improved tolerability, yet a fundamental paradox persists: the dose that minimizes side effects and rebound may be insufficient to halt axial elongation in children at greatest risk. This perspective article argues that atropine therapy faces an \u201cimpossible triangle\u201d of dose-dependent efficacy, rebound magnitude, and tolerability, which precludes any single-concentration solution applicable to the entire pediatric population. We propose a redefinition of the risk\u2013benefit assessment framework, moving beyond exclusive reliance on refractive error toward a multidimensional evaluation centered on axial length control, age at treatment initiation, and environmental factors such as outdoor activity. An integrated, stepped-titration strategy that combines pharmacological, optical, and behavioral interventions is advocated. Looking ahead, we call for the development of a multicentre, real-world evidence base with mandatory long-term washout data, which is essential to inform personalized, public-health-oriented myopia management aimed not at temporary dioptric stabilization but at the durable prevention of blindness.<\/jats:p>","DOI":"10.3389\/fpubh.2026.1878312","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:55:19Z","timestamp":1782280519000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Paradox of atropine in myopia control: exploring dose-dependent efficacy, rebound effects, and optimal risk-benefit balance\u2013a perspective"],"prefix":"10.3389","volume":"14","author":[{"given":"Ya-zhen","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Xi'an People's Hospital (Xi'an Fourth Hospital)","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Xi'an People's Hospital (Xi'an Fourth Hospital)","place":["Xi'an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.1167\/iovs.18-25957","article-title":"IMI - defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies","volume":"60","author":"Flitcroft","year":"2019","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.35772\/ghm.2020.01007","article-title":"Pathologic myopia: an overview of the current understanding and interventions","volume":"2","author":"Ueta","year":"2020","journal-title":"Glob Health Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"101156","DOI":"10.1016\/j.preteyeres.2022.101156","article-title":"Myopia: histology, clinical features, and potential implications for the etiology of axial elongation","volume":"96","author":"Jonas","year":"2023","journal-title":"Prog Retin Eye Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.aopr.2024.06.003","article-title":"Complications of high myopia: an update from clinical manifestations to underlying mechanisms","volume":"4","author":"Du","year":"2024","journal-title":"Adv Ophthalmol Pract Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 001% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/opo.12052","article-title":"How does atropine exert its anti-myopia effects?","volume":"33","author":"McBrien","year":"2013","journal-title":"Ophthalmic Physiol Opt."},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens."},{"key":"B14","doi-asserted-by":"publisher","first-page":"29392","DOI":"10.1038\/s41598-025-12800-2","volume":"15","author":"Xiang","year":"2025","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1343698","DOI":"10.3389\/fphar.2024.1343698","article-title":"Myopia progression after cessation of atropine in children: a systematic review and meta-analysis","volume":"15","author":"Lee","year":"2024","journal-title":"Front Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","article-title":"Five-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 4 report","volume":"131","author":"Zhang","year":"2024","journal-title":"Ophthalmology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.preteyeres.2012.06.004","article-title":"The complex interactions of retinal, optical and environmental factors in myopia aetiology","volume":"31","author":"Flitcroft","year":"2012","journal-title":"Prog Retin Eye Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaophthalmol.2026.0436","article-title":"Discontinuation approach and follow-up of low-concentration atropine for myopia progression: eight-year results of the lamp randomized clinical trial","volume":"144","author":"Zhang","year":"2026","journal-title":"JAMA Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1080\/09286586.2025.2612156","article-title":"Expert opinion on myopia tapering: strategies for managing myopia progression","volume":"33","author":"Chen","year":"2026","journal-title":"Ophthalmic Epidemiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100923","DOI":"10.1016\/j.preteyeres.2020.100923","article-title":"Efficacy in myopia control","volume":"83","author":"Brennan","year":"2021","journal-title":"Prog Retin Eye Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"M106","DOI":"10.1167\/iovs.18-25958","article-title":"IMI - interventions myopia institute: interventions for controlling myopia onset and progression report","volume":"60","author":"Wildsoet","year":"2019","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"CD004916","DOI":"10.1002\/14651858.CD004916.pub4","article-title":"Interventions to slow progression of myopia in children","volume":"1","author":"Walline","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/aos.13403","article-title":"Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review","volume":"95","author":"Xiong","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.exer.2013.02.007","article-title":"An updated view on the role of dopamine in myopia","volume":"114","author":"Feldkaemper","year":"2013","journal-title":"Exp Eye Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2012.11.009","article-title":"Outdoor activity during class recess reduces myopia onset and progression in school children","volume":"120","author":"Wu","year":"2013","journal-title":"Ophthalmology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/bjophthalmol-2017-311266","article-title":"Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling","volume":"102","author":"Fricke","year":"2018","journal-title":"Br J Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/bjophthalmol-2020-318367","article-title":"One-year myopia control efficacy of spectacle lenses with aspherical lenslets","volume":"106","author":"Bao","year":"2022","journal-title":"Br J Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/OPX.0000000000001367","article-title":"Myopia control: why each diopter matters","volume":"96","author":"Bullimore","year":"2019","journal-title":"Optom Vis Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/eye.2012.49","article-title":"Comparison of measurements of time outdoors and light levels as risk factors for myopia in young Singapore children","volume":"26","author":"Dharani","year":"2012","journal-title":"Eye."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1167\/iovs.14-15978","article-title":"Light exposure and eye growth in childhood","volume":"56","author":"Read","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1878312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:55:20Z","timestamp":1782280520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1878312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":32,"alternative-id":["10.3389\/fpubh.2026.1878312"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1878312","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1878312"}}